{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:31:43Z","timestamp":1778776303780,"version":"3.51.4"},"reference-count":178,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Clozapine remains the only effective antipsychotic drug for treatment-resistant schizophrenia (TRS), yet it continues to be markedly underused in most industrialized countries including Germany. Previous studies have identified prescriber-related factors such as concerns about adverse drug reactions, the burden of mandatory monitoring, and limited experience with clozapine use and TRS recognition as major contributors to this persistent underutilization. However, these issues have not been studied for the German healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To investigate prescriber attitudes toward clozapine use for schizophrenia in Germany and identify related treatment barriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Cross-sectional, web-based survey study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a web-based cross-sectional survey using PsyToolkit. Our questionnaire assessed clinicians\u2019 demographics, familiarity with relevant national guidelines, practical experience with clozapine and formalized training in its use, perceived treatment barriers, and presumptions about patients\u2019 attitudes toward clozapine. Data were predominantly analyzed descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 155 psychiatrists\u2014most of them board-certified and nearly all regular clozapine prescribers for schizophrenia\u2014completed the survey. Most participants were familiar with guideline recommendations for clozapine initiation. However, even among them, most preferred to attempt at least one trial of antipsychotic polypharmacy before starting clozapine. Formalized training had a positive impact on knowledge regarding clozapine\u2019s effectiveness in reducing negative symptoms, aggressive behavior, and suicidality. While most participants acknowledged clozapine\u2019s effectiveness in reducing all-cause mortality, only a small proportion of participants acknowledged its effectiveness in reducing cardiovascular mortality. Notably, three quarters of participants presumed that patients would prefer standard antipsychotics over clozapine. Monitoring requirements and concerns regarding weight gain and blood dyscrasia were ranked as the main barriers impeding clozapine use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We identified several modifiable prescriber-related factors limiting clozapine use for schizophrenia in Germany. Implementing mandatory targeted training programs during residency and regular use of shared decision-making to emphasize the patients\u2019 perspective might facilitate a timelier and widespread use of clozapine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20451253261434380","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:41:30Z","timestamp":1776426090000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Adult psychiatrists\u2019 views on clozapine prescribing for schizophrenia in Germany\u2014an online survey"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-5739","authenticated-orcid":false,"given":"Mishal","family":"Qubad","sequence":"first","affiliation":[{"name":"Goethe University Frankfurt, University Hospital, Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, Heinrich-Hoffmann-Str. 10, Frankfurt am Main 60528, Germany"},{"name":"Ernst Str\u00fcngmann Institute of the Max Planck Society, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3439-8209","authenticated-orcid":false,"given":"Ida Marie","family":"Ehret","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital, Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian J.","family":"Bachmann","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Ulm University, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2021-0358","authenticated-orcid":false,"given":"Robert A.","family":"Bittner","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital, Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, Frankfurt am Main, Germany"},{"name":"Ernst Str\u00fcngmann Institute of the Max Planck Society, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/00048674241274314"},{"issue":"5","key":"e_1_3_4_4_2","first-page":"448","article-title":"Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates","volume":"45","author":"Diniz E","year":"2023","unstructured":"Diniz E, Fonseca L, Rocha D, et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Braz J Psychiatry 2023; 45(5): 448\u2013458.","journal-title":"Braz J Psychiatry"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18com12123"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999709113338"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-019-0090-z"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000435"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291716002014"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2021.61"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.MY20096AH1C"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbj067"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.600"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00032-X"},{"key":"e_1_3_4_17_2","first-page":"103291","article-title":"Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis","volume":"84","author":"Samara M","year":"2025","unstructured":"Samara M, Lappas AS, Pinioti E, et al. Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis. E Clinical Medicine 2025; 84: 103291.","journal-title":"E Clinical Medicine"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2022.1"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20994"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0161-2"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13291"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2022.117"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2022.12.011"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1702"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231158152"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab087"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20699"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbl003"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2004.05.015"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.6.3.5"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.82"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/026988110101500209"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04718yel"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2022.103192"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13267"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby052"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01613-2"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00366-3"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaa060"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000871"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae065"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2024.02.035"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2024.12.015"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717718167"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.01.064"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221103353"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.4103\/jspf.JSPF_3_23"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12018"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00297-4"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-020-09839-x"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1017\/S146114571100201X"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00932-2"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1192\/bja.2025.12"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1192\/bja.2021.24"},{"key":"e_1_3_4_56_2","unstructured":"H\u00f6glinger G. TCea. Parkinson-Krankheit S2k-Leitlinie 2023. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie https:\/\/www.dgn.org\/leitlinie\/parkinson-krankheit (accessed 7th December 2025)."},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-2560-4028"},{"key":"e_1_3_4_58_2","unstructured":"Leitliniengruppe DeVHfrd. S3-Leitlinie Schizophrenie. Langfassung https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/038\u2013009.html (accessed 30th November 2025)."},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00031-8"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12742"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.105833"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.04.012"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027694"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1192\/pb.29.10.377"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12294"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2020.110"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-021-00847-0"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.03.029"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12193"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2015.09.013"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-023-00423-3"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-085956"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201700162"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000269"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108100320"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.10.011"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-023-00353-0"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221141222"},{"key":"e_1_3_4_79_2","article-title":"Clozapine use at a specialised psychiatric hospital in Johannesburg","volume":"29","author":"Ord KL","year":"2023","unstructured":"Ord KL, Marais B. Clozapine use at a specialised psychiatric hospital in Johannesburg. S Afr J Psychiatr 2023; 29: 1999.","journal-title":"S Afr J Psychiatr"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04179-5"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1123246"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2016.14.3.286"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045125314566808"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.05.046"},{"issue":"7","key":"e_1_3_4_85_2","article-title":"Clozapine prescribing practice and trends in Qatar: first national observational study","volume":"12","author":"Wadoo O","year":"2022","unstructured":"Wadoo O, Latoo J, Alabdulla M, et al. Clozapine prescribing practice and trends in Qatar: first national observational study. Brain Behav 2022; 12(7): e2617.","journal-title":"Brain Beha"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14231"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgac042"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-025-00570-9"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000188"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21ac14000"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgab043"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114970"},{"key":"e_1_3_4_93_2","first-page":"74","article-title":"Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?","volume":"268","author":"Schulte PFJ","year":"2024","unstructured":"Schulte PFJ, Veerman SRT, Bakker B, et al. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed? Schizophrenia Res 2024; 268: 74\u201381.","journal-title":"Schizophrenia Res"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00098-7"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241262767"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.1816"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2025.2479601"},{"key":"e_1_3_4_98_2","unstructured":"I SB. Gesundheitsausgaben 2023: Finanzierungsbeitrag des Staates um fast ein Drittel gesunken https:\/\/www.destatis.De\/DE\/Presse\/Pressemitteilungen\/2025\/07\/PD25_268_23611.html (2025 accessed 7 December 2025)."},{"key":"e_1_3_4_99_2","unstructured":"II SB. Deutschland mit h\u00f6chsten Gesundheitsausgaben der EU https:\/\/www.destatis.de\/DE\/Presse\/Pressemitteilungen\/2025\/07\/PD25_268_23611.html (2025 accessed 7 December 2025)."},{"key":"e_1_3_4_100_2","unstructured":"III SB. Krankenversicherungsschutz https:\/\/www.destatis.de\/DE\/Themen\/Arbeit\/Arbeitsmarkt\/Qualitaet-Arbeit\/Dimension\u20132\/krankenversicherungsschutz.html (accessed 7 December 2025)."},{"issue":"41","key":"e_1_3_4_101_2","first-page":"8262","article-title":"Menschen ohne Krankenversicherung: Ein oft \u00fcbersehenes Problem","volume":"119","author":"Kurz C.","year":"2022","unstructured":"Kurz C. Menschen ohne Krankenversicherung: Ein oft \u00fcbersehenes Problem. Dtsch Arztebl International 2022; 119(41): 8262.","journal-title":"Dtsch Arztebl Internati"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-12847-x"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-006-0696-9"},{"key":"e_1_3_4_104_2","unstructured":"\u00c4rzteZeitung. Sozialhilfe muss f\u00fcr Notfallbehandlung bei Ausl\u00e4ndern ohne Krankenversicherung zahlen https:\/\/www.aerztezeitung.de\/Wirtschaft\/Sozialhilfe-muss-fuer-Notfallbehandlung-bei-Auslaendern-ohne-Krankenversicherung-zahlen\u2013441194.html (2023 accessed 7 December 2025)."},{"key":"e_1_3_4_105_2","volume-title":"Healthy in Germany everything you need to know about the healthcare system in Germany","author":"Federal Ministry of Health","year":"2025","unstructured":"Federal Ministry of Health. Healthy in Germany everything you need to know about the healthcare system in Germany. Berlin: Federal Ministry of Health, 2025."},{"key":"e_1_3_4_106_2","unstructured":"eurostat. Healthcare resource statistics - beds https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Healthcare_resource_statistics_-_beds (2025 accessed 7 December 2025)."},{"key":"e_1_3_4_107_2","unstructured":"OECD. State of Health in the EU Germany Country Health Profile 2023 2023."},{"key":"e_1_3_4_108_2","unstructured":"ReportLinker. Psychiatric Care Beds in Hospitals in Germany https:\/\/www.reportlinker.com\/dataset\/a070643524817edea591f6ec910549001c86c4b6 (accessed 7 December 2025)."},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03163-9"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-025-01895-7"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-0918-6071"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-006-0117-4"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2021.20111596"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.11.031"},{"key":"e_1_3_4_115_2","unstructured":"Bechdolf A. Psychocheck https:\/\/www.psycho-check.com (accessed 7 December 2025)."},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291710000371"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-015-1093-3"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-012-0628-0"},{"key":"e_1_3_4_119_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-004-0767-z"},{"key":"e_1_3_4_120_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-015-4417-3"},{"key":"e_1_3_4_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2014.01.002"},{"key":"e_1_3_4_122_2","unstructured":"German Medical Association. Medical organisations and associations https:\/\/www.bundesaerztekammer.de\/en\/work-and-training-in-germany\/organisation-and-association (accessed 7th December 2025)."},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14242"},{"key":"e_1_3_4_124_2","article-title":"A comparison of medical education in Germany and the United States: from applying to medical school to the beginnings of residency","volume":"15","author":"Zavlin D","year":"2017","unstructured":"Zavlin D, Jubbal KT, No\u00e9 JG, et al. A comparison of medical education in Germany and the United States: from applying to medical school to the beginnings of residency. Ger Med Sci 2017; 15: Doc15.","journal-title":"Ger Med Sci"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ap.31.4.309"},{"key":"e_1_3_4_126_2","volume-title":"(Muster-)Weiterbildungsordnung 2018","author":"Association GM","year":"2025","unstructured":"Association GM. (Muster-)Weiterbildungsordnung 2018. In: Association GM (ed.) German Medical Association, 2025."},{"key":"e_1_3_4_127_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-023-03671-x"},{"key":"e_1_3_4_128_2","doi-asserted-by":"publisher","DOI":"10.1192\/S1749367600001922"},{"key":"e_1_3_4_129_2","unstructured":"GesundBundDE. Hospitals \u2013 key information about their duties differences and how to find a hospital https:\/\/gesund.bund.de\/en\/hospitals."},{"key":"e_1_3_4_130_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155982"},{"key":"e_1_3_4_131_2","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG); . Health care in Germany: Learn More \u2013 The German healthcare system https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK298834\/ (2006 accessed 30 November 2025)."},{"key":"e_1_3_4_132_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_4_133_2","doi-asserted-by":"publisher","DOI":"10.3758\/BRM.42.4.1096"},{"key":"e_1_3_4_134_2","doi-asserted-by":"publisher","DOI":"10.1177\/0098628316677643"},{"key":"e_1_3_4_135_2","unstructured":"Leitliniengruppe DeVHfd. S3-Leitlinie Schizophrenie Langfassung https:\/\/www.dgppn.de\/_Resources\/Persistent\/a3691a191295cc21e79ca3dea76cf04303fdb29a\/038-009m_S3_Schizophrenie_2025-10.pdf (2025 accessed 20 October 2025)."},{"key":"e_1_3_4_136_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304996"},{"key":"e_1_3_4_137_2","unstructured":"IBM Corp. (2020). IBM SPSS Statistics for Windows (Version 31.0) [Computer software]. IBM Corp."},{"key":"e_1_3_4_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.12.102"},{"key":"e_1_3_4_139_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01100-4"},{"key":"e_1_3_4_140_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13398"},{"key":"e_1_3_4_141_2","unstructured":"Agency EM. Clozapine - direct healthcare professional communication (DHPC) https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/clozapine (2025 accessed 20 October 2025)."},{"key":"e_1_3_4_142_2","unstructured":"Federal Institute for Drugs and Medical Devices. Direct Healthcare Professional Communication (DHPC) on Clozapine: revised recommendations for routine blood count monitoring with regard to the risk of agranulocytosis https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/EN\/RHB\/2025\/rhb-clozapin.html (2025 accessed 20 October 2025)."},{"key":"e_1_3_4_143_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320928167"},{"key":"e_1_3_4_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2020.05.030"},{"key":"e_1_3_4_145_2","first-page":"1","article-title":"Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis","volume":"2025","author":"Wagner E","unstructured":"Wagner E, Korman N, Solmi M, et al. Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis. Br J Psychiatry 2025: 1\u20139.","journal-title":"Br J Psychiatry"},{"key":"e_1_3_4_146_2","doi-asserted-by":"publisher","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_585_23"},{"key":"e_1_3_4_147_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1625-6388"},{"key":"e_1_3_4_148_2","first-page":"94","article-title":"A case series of clozapine titrations affected by inflammatory processes","volume":"268","author":"Leung JG","year":"2024","unstructured":"Leung JG, Allen ND, Markota M. A case series of clozapine titrations affected by inflammatory processes. Schizophrenia Res 2024; 268: 94\u201397.","journal-title":"Schizophrenia Res"},{"key":"e_1_3_4_149_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12421"},{"key":"e_1_3_4_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.06.003"},{"key":"e_1_3_4_151_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2024.113"},{"key":"e_1_3_4_152_2","doi-asserted-by":"publisher","DOI":"10.1186\/s43045-020-00059-4"},{"key":"e_1_3_4_153_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjb.2018.67"},{"key":"e_1_3_4_154_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.042895"},{"key":"e_1_3_4_155_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201600041"},{"key":"e_1_3_4_156_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13280"},{"key":"e_1_3_4_157_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2012.01863.x"},{"key":"e_1_3_4_158_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40596-013-0030-6"},{"key":"e_1_3_4_159_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.116.193458"},{"key":"e_1_3_4_160_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.2247"},{"key":"e_1_3_4_161_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2011.01711.x"},{"key":"e_1_3_4_162_2","first-page":"223","article-title":"Patient and caregivers perspective about clozapine: a systematic review","volume":"268","author":"Grover S","year":"2024","unstructured":"Grover S, Naskar C. Patient and caregivers perspective about clozapine: a systematic review. Schizophrenia Res 2024; 268: 223\u2013232.","journal-title":"Schizophrenia Res"},{"key":"e_1_3_4_163_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ap.11090159"},{"key":"e_1_3_4_164_2","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2025.10024"},{"key":"e_1_3_4_165_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.10.1181"},{"key":"e_1_3_4_166_2","article-title":"A randomized controlled trial of an extension for community healthcare outcomes (ECHO) Tele-mentoring program to increase clozapine utilization","author":"Kelly DL","year":"2025","unstructured":"Kelly DL, Hunt J, Vyas G, et al. A randomized controlled trial of an extension for community healthcare outcomes (ECHO) Tele-mentoring program to increase clozapine utilization. Schizophr Bull 2025: sbaf067.","journal-title":"Schizophr Bull"},{"key":"e_1_3_4_167_2","doi-asserted-by":"publisher","DOI":"10.2196\/16504"},{"key":"e_1_3_4_168_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12327"},{"key":"e_1_3_4_169_2","unstructured":"Cotes RO. Persistent Symptoms: Treatment Assessment and Recovery (PSTAR) https:\/\/redcap.emory.edu\/surveys\/?s=4PYL8AJTAR (accessed 20 October 2025)."},{"key":"e_1_3_4_170_2","unstructured":"Ulm U. Medizinische Kinderschutzhotline https:\/\/kinderschutzhotline.de\/course\/view.php?id=8 (accessed 20 October 2025)."},{"key":"e_1_3_4_171_2","doi-asserted-by":"publisher","DOI":"10.1111\/eip.13578"},{"key":"e_1_3_4_172_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2020.89"},{"key":"e_1_3_4_173_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04389-0"},{"key":"e_1_3_4_174_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-025-00370-1"},{"key":"e_1_3_4_175_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-2374-2386"},{"key":"e_1_3_4_176_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-021-00223-7"},{"key":"e_1_3_4_177_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03210-8"},{"key":"e_1_3_4_178_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00411-5"},{"key":"e_1_3_4_179_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13762"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261434380","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20451253261434380","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261434380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:54:04Z","timestamp":1777593244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20451253261434380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":178,"alternative-id":["10.1177\/20451253261434380"],"URL":"https:\/\/doi.org\/10.1177\/20451253261434380","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"20451253261434380"}}